Cracking the case: The diagnosis and treatment of a complex high-grade endometrial carcinoma with hepatoid, endometrioid, serous features and somatically derived yolk sac tumor component in a 50 year old female

Cailin O'Connell; Sylvia Jang; Paloma Monroig-Bosque; Anne Alaniz

doi:10.1016/j.gore.2023.101207

Cracking the case: The diagnosis and treatment of a complex high-grade endometrial carcinoma with hepatoid, endometrioid, serous features and somatically derived yolk sac tumor component in a 50 year old female

Gynecol Oncol Rep. 2023 May 25:47:101207. doi: 10.1016/j.gore.2023.101207. eCollection 2023 Jun.

Authors

Cailin O'Connell¹, Sylvia Jang², Paloma Monroig-Bosque², Anne Alaniz³

Affiliations

¹ Texas A&M School of Engineering Medicine, United States.
² Department of Pathology and Genomic Medicine, Houston Methodist Hospital, United States.
³ Houston Methodist Gynecologic Oncology Associates, United States.

Abstract

•Alpha-fetoprotein secreting tumors in gynecologic cancers have a broad differential.•Surgical pathology may provide a more comprehensive picture of tumor heterogeneity than initial biopsy.•Yolk Sac Tumor components intermixed with carcinoma points towards a somatic derivative rather than a collision tumor.•Alpha-fetoprotein can be trended over time to gauge response to treatment of cancers that produce the protein.

Keywords: Alpha-fetoprotein; Endometrial carcinoma; Endometroid; Hepatoid; Uterine cancer; Yolk sac tumor.

Publication types

Case Reports